MEDIVIR AB - Many Cooks - Likely to Steal the Show
Impressive clinical data presentation at AASLD ‘11 highlighted the increasing competition and fast pace of development of “IFN free oral option” in HCV therapy area. This has cast a shadow on the commercial potential of TMC435 (Protease Inhibitor, PhIII, partnered with Tibotec/JNJ) and its life span. Management changes, uncertainty about marketing strategies and dependence on TMC435 has resulted……. For more detail, please read our report released on 16th November on MVIR titled “Too Many Cooks -Likely to Steal the Show”
COMPANIES MENTIONED
MEDIVIR AB
MEDIVIR AB
